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Abst rac t
Chromoblastomycosis is a chronic fungal infection of the skin and subcutaneous tissue. The infection usually results 
from a traumatic injury and inoculation of microorganism from a specific group of dematiaceous fungi (usually 
Fonsecaea pedrosoi, Phialophora verrucosa, Cladophialophora carrionii). In the tissues fungi produce characteristic 
sclerotic cells or muriform cells. Dermal lesions can range from small nodules to large papillary-like eruptions. The 
disease has been described worldwide but the prevalence is higher in rural populations in countries with a tropical 
or subtropical climate, such as Madagascar in Africa and Brazil in South America. Diagnostic techniques are based 
on direct examination, culture and histopathology. Despite a variety of treatment modalities, which include long 
courses of antifungals, surgical excision and destructive physical therapies, the disease remains one of the most 
difficult deep mycotic infections to eradicate.
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Definition and history of research 
Chromoblastomycosis (CBM) is defined as a chronic 
cutaneous and subcutaneous fungal infection resulting 
from traumatic implantation of certain dematiaceous fun-
gi through the skin. The aetiological agents gain entrance 
through transcutaneous puncture wounds, usually by parts 
of plants. The definition of CBM is occasionally narrowed 
to the disease caused by fungus of the Chaetothyriales or-
der [1]. In a typical manifestation the dermal lesions form 
cauliflower-like nodules. In the infected tissue, characteris-
tic dark-coloured, thick-walled, muriform cells i.e. sclerotic 
cells (Medlar bodies) are observed (Figure 1), which is a his-
topathological criterion for the diagnosis [1–4].
The disease was initially considered to be closely 
related to blastomycosis, which is a different type of 
a fungal infection caused by dimorphic fungi of the Blas-
tomyces dermatitis sp. It is reflected in the name of the 
disease, which suggests it is a fungal infection caused by 
pigmented Blastomyces fungus (Greek chroma, ~atos = 
complexion, skin colour, + Blastomyces Greek blastós = 
sprout, bud + mykes = fungus + osis Greek suffix denot-
ing the state of something/somebody). However, the dis-
eases are differentiated by the type of the fungal cells in 
the host tissue. In CBM, cell division of the fungi, which 
infect the tissue occurs as a result of producing septa i.e. 
meristematically (Greek meristos = divided) and not by 
budding, which is present in the yeast phase of Blasto-
myces [2].
The term CBM is semantically closely related to phae-
ohyphomycosis, a fungal infection also caused by dema-
tiaceous fungi, however production of Medlar bodies 
(sclerotic cells) in the tissues does not occur.
For many years various names have been proposed 
for this disease entity, some of which are presented in 
Table 1. Eventually in 1992, the International Society for 
Human and Animal Mycology (ISHAM) decided that the 
term Chromoblastomycosis was the proper one [5]. Cur-
rently the disease is defined in the International Classi-
fication of Diseases (ICD) as follows: ICD-9 no 117.2, ICD 
10-B43.
In 1911, Alexandre Pedroso in Sao Paulo, Brazil, stud-
ied the cases with nodular and ulcerous dermal lesions 
on the foot and on the shin. He named the disease 
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Figure 1. Sclerotic cells (Medlar bodies) inside Langhans gi-
ant cell obtained histopathologically – skin biopsy specimen
blastomycose negra. However, Pedroso and Jose Maria 
Gomes published their observations as late as in 1920 
[6]. In the meantime in 1914, Max Rudolph, a German 
physician living in Brazil, described six cases of the dis-
ease which he named figueira (fig tree). Moreover, he 
was able to isolate dematiaceous fungi from 4 cases, 
which he recognised as belonging to the variety of Blas-
tomycetes. He managed to infect white rats and monkeys 
with the fungi. The descriptions of the disease and the 
mycological discoveries reported by Rudolph indicate 
that it was the same fungus that had been discovered 
by Pedroso a few years earlier [7, 8].
A year later, in 1915, Medlar [9] and Lane [10] pub-
lished in the USA a case of a patient from Boston who 
suffered from a disease caused by an unknown type of 
a fungus. They found lesions to be blastomycetic. The le-
sions included a number of spherical, pigmented, parasit-
ic cells (Medlar bodies). The fungus was carefully studied 
and was given the name Phialophora verrucosa.
In 1922, Brumpt [11] demonstrated that it was not 
Phialophora verrucosa which caused the infection in the 
case described by Pedroso, but a different fungus which 
he named Hormodendrum pedrosoi. In 1923, Fonseca and 
Leao described a different method of sporulation for this 
fungus, which linked it with the Acrotheca genus (spe-
cies re-classification to the Acrotheca pedrosoi genus). In 
1922, Terra et al. used the term “Chromoblastomycosis” 
for the first time [12 cited by 13].
In 1935, another method of sporulation was discov-
ered in Acrotheca (Hormodendrum) pedrosoi. In this 
method spores were created in phialides, which related 
the fungus to the Phialophora genus described by Medlar 
(name Phialophora pedrosoi was suggested). Three dif-
ferent types of conidiation in the same organism resulted 
in many misleading descriptions of the fungus using var-
ious names related to species and genus. Some most sig-
nificant synonymous names are presented in the Table 1.
In 1935, Carrion in Puerto Rico described the third 
aetiological agent of CBM – Hormodendrum compacta. 
Puerto Rican fungus had all three methods of sporulation 
characteristic of Hormodendrum, but also demonstrated 
individual features so that it could be recognised as a dif-
ferent species. In 1936, Pablo Negroni proposed a generic 
name Fonsecaea, which was accepted as correct. It has 
been used until now.
In the 1950s, another fungal species was added to 
the aetiological agents of CBM, namely Cladosporium 
(currently Cladophialophora) carrionii, first described by 
Trejos in 1954. It solved the problem of describing an in-
creasing number of species classified in the Cladospori-
um genus, which were responsible for CBM cases [14].
Studies on similarity and aetiological agents of CBM 
are still continued. In 2004, scientists from the University 
of Chiba in Japan found that there is no difference in sub-
unit ribosomal DNA D1/D2 domain sequence between 
F. pedrosoi and F. compacta, which may indicate that the 
latter is merely a morphological variation of the first [15]. In 
the same year, Sybren de Hoog et al. re-classified the Botry-
oides monophora sp. It was deposited in the culture collec-
tion CBS 269.37 to the new Fonseca genus. And thus, a new 
species was created i.e. Fonsecaea monophora, morphologi-
Table 1. Synonymous names of aetiological agents  
of chromoblastomycosis
Synonyms of Fonsecaea pedrosoi (Brumpt) Negroni 1936
Hormodendrum pedrosoi Brumpt 1922
Acrotheca pedrosoi (Brumpt) Fonseca & Leão 1923
Trichosporum pedrosianum (Brumpt) M. Ota 1927
Trichosporum pedrosoi (Brumpt) Brumpt 1927
Gomphinaria pedrosoi (Brumpt) C.W. Dodge 1935
Hormodendroides pedrosoi (Brumpt) M. Moore & F.P.  
Almeida 1936
Phialophora pedrosoi (Brumpt) Redaelli & Cif. 1941
Carrionia pedrosoi (Brumpt) Bric.-Irag. 1942
Rhinocladiella pedrosoi (Brumpt) Schol-Schwarz 1968
Synonyms* of Fonsecaea compacta (Carrion) Carrion 1940
Hormodendrum compactum Carrion 1935
Phialoconidiophora compacta (Carrion) M. Moore & F.P.  
Almeida 1936 
Phialophora compacta (Carrion) Redaelli & Cif. 1942
Rhinocladiella compacta (Carrion) Schol-Schwarz 1968
Synonyms of Cladophialophora carrionii (Trejos) de Hoog, 
Kwon-Chung & McGinnis 1995
Cladosporium carrionii Trejos 1954
Although the term F. compacta has synonymous names, it is already 
a synonym of F. pedrosoi.
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cally very similar to F. pedrosoi. Currently, standard diagnosis 
does not differentiate between these species narrowing the 
diagnosis to the F. pedrosoi/monophora complex [16].
Aetiological agents
The most frequent aetiological agents of CBM are the 
following species: Fonsecaea pedrosoi (Figures 2 and 3), 
Phialophora verrucosa and Cladophialophora carrionii. Rhi-
nocladiella aquaspersa [17, 18] and Exophiala dermatitidis 
are less frequently reported. It has also been observed that 
Exophiala jeanselmei [19–21] and E. spinifera [22–25], nor-
mally responsible for the development of phaeohyphomy-
cosis, produce muriform cells in typical lesions of CBM. In 
recent years other species that may be the agents of CBM 
have been described: Fonsecaea monophora [26, 27], Fon-
secaea nubica [28] and Phialophora richardsiae [29].
All the species listed above belong to the Herpotrichiel-
laceae family of the Chaetothyriales order within the phy-
lum of sac fungi (Ascomycota). Members of this family are 
related to teleomorphic form of Capronia sp. The teleomor-
phic form is isolated mainly from wood and Basidiomyco-
ta, whereas parasitic forms occur in an anamorphic form 
(asexual reproduction). These fungi frequently grow meri-
stematically (this type of growth may be observed in Med-
lar bodies in the tissue of mammals infected with CBM 
and in plant tissues) and in a yeast-like form. Furthermore, 
due to melanin production, the fungi are characterised by 
dematiaceous mycelium, therefore, this type of microor-
ganisms is defined in English-language literature as black 
yeast or black yeast-like fungi [30].
In the literature, cases of CBM caused by dematiaceous 
fungi of different families and orders can be found. These 
infections affect mainly individuals with the impaired im-
mune system [31]. In the casuistic literature well-document-
ed cases of fungal infections are reported. These are Aureo-
basidium pullulans in a patient after liver transplant [32] and 
Rhytidhysteron sp. in a patient following kidney transplant 
in India [33]. There are also poorly documented cases of 
CBM caused by different dematiaceous fungi. It is a case 
of a dermal lesion on the palm caused by Chaetomium fu-
nicola in a healthy elderly patient in Panama [34], however 
without definitely recognised muriform cells in the tissue, 
which could be spores or fragments of hyphae of the fungus 
[35]. Furthermore, in the Centraalbureau voor Schimmelcul-
tures (CBS) Fungal Biodiversity Centre collection, a strain of 
Catenulostroma chromoblastomycosum is deposited with 
the information that it is the case of CBM from Zaire [36] 
(currently Democratic Republic of the Congo). However, no 
reliable clinical description exists whether the biopsy was 
done and whether the characteristic features of CBM were 
identified [35].
Geographical distribution
The disease is prevalent in the world. However, most 
cases are reported in humid tropical and subtropical 
Figure 3. Fonsecaea pedrosoi colony on SGA medium after 
14 days of incubation
Figure 2. Conidiophores of F. pedrosoi – Cotton Blue Lacto-
phenol staining
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climate areas of America, Asia and Africa. The highest 
prevalence rates are reported in Mexico (Oaxaca and 
Veracruz) [37], Cuba [38], Venezuela [39], the Dominican 
Republic, Colombia [40] and Brazil (mainly in the region 
of Amazonia) [13, 41, 42] (Figure 4).
The first case of CBM outside American continents 
was reported in the Pasteur Institute in Algiers in 1927 
[43]. In Africa most cases were reported in Madagascar 
(1955–1994, 1323 cases) [44] and in the South Africa.
In Asia CBM is most frequently reported in Japan [45], 
Sri Lanka [46] and India [47]. Furthermore, the disease is 
fairly common in China, especially in Shandong and He-
nan provinces. The first case was reported in 1952. Since 
that time over 500 cases from 20 provinces have been 
reported [48]. In Japan about 10 cases of CBM are report-
ed annually. The occurrence rate of individual species in 
the last two decades of the 20th century was as follows: 
F. pedrosoi – 71%, E. jeanselmei – 20%, Phialophora verru-
cosa – 4.5%, Exophiala dermatitidis – 2% [49].
Not many cases have been reported in Australia. They 
are mostly caused by Cladophialophora carrionii [50, 51].
In a temperate climate, e.g. in Europe, CBM is rare 
and is rather a non-indigenous disease. In 1928, in 
Leningrad, Tschernjawski identified CBM in a Polish 
woman who most likely developed the infection fall-
ing off a horse near Vilnius. It was presumably the first 
described case of CBM in Europe. The isolated fungus 
was classified into Hormodendrum rossicum sp., which 
later became synonymous with F. pedrosoi [52]. In 1938, 
14 cases of CBM were reported in Russia. However, all of 
Figure 4. Geographical distribution of chromoblastomycosis based on CDC [65], and the PubMed Base review
them occurred in an Asian region of the country [53]. In 
Europe, indigenous cases of CBM were reported in Fin-
land [54]. Furthermore, in former Czechoslovakia [55–57] 
and in Germany [58], cases of the disease were also re-
ported. In the United Kingdom, the first described cases 
were related to immigrants from Jamaica and Ceylon [53]. 
The first case of CBM in Poland was reported in 1972 
in Przegląd Dermatologiczny [59]. Up to now 4 document-
ed cases of this disease in Poland have been known [60].
Currently, studies on the relationship between geo-
graphical distribution of fungal species/varieties respon-
sible for CBM and the forms of infections are conducted. 
Differences in the species which are the agents of CBM have 
been observed, depending on the region. F. pedrosoi is re-
lated to humid areas of a tropical and subtropical climate, 
whereas C. carrionii is dominant in a semi-arid climate [37, 
39, 42, 50, 61]. It is particularly visible in Madagascar where 
in the tropical rainforest area in the north of the island, 
F. pedrosoi is prevalent, whereas in the south of the island 
with the “thorny desert” climate, Cladophialophora carrionii 
is more common [44, 62]. In the north of China, C. carrionii 
and in the south F. monophora are prevalent [48].
Based on the internal transcribed spacer regions (ITS) of 
fungal DNA analysis, the Fonsecaea genus was divided into 
three groups; group A – F. pedrosoi, group B – F. monophora 
and group C – different species of the Fonsecaea genus [31]. 
Further studies of Yaguchi et al. [63] and Xi et al. [48] re-
sulted in a division of the F. pedrosoi group into subgroups, 
i.e. A1 and A2 and the F. monophora group into subgroups, 
i.e. B1, B2 and B3. It was found that individual subgroups 
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occur in different parts of the world. It may be significant 
due to the relation of aetiological agents and geographical 
distribution with the form of CBM. Fonsecaea pedrosoi ap-
pears to be a pathogen closely related to CBM only, whereas 
F. monophora is an opportunistic pathogen with diverse 
clinical spectrum [16].
It was found that within the Fonsecaea genus the A1 
subgroup occurs in Thailand, Australia, South America, Af-
rica, South and East China; the A2 subgroup in Central and 
South America; the B1 subgroup in Central and South Amer-
ica, and South China; the B2 subgroup in Central America, 
Japan and East China. Finally, the B3 subgroup occurs in the 
USA, the United Kingdom and South China [48–63].
In the study on South Korean isolates, a high differ-
entiation was observed – strains of F. pedrosoi similar to 
the strains reported in South and East China, two groups 
of F. monophora similar to the strains from South and 
East China and Japan. Additionally, a strain identical to 
the one in Costa Rica was identified and a strain simi-
lar to the Thai strains was isolated from an immigrant 
(which meant that the infection had developed earlier in 
Thailand) [64]. Figure 3 shows a high prevalence of CBM.
Epidemiology and ecology
Sources of infection
The discovery of natural habitats of the fungi and the 
source of fungal parasitic infection for humans is crucial for 
understanding the development of pathogenicity in those 
organisms [65]. Fungi responsible for CBM are found in the 
environment in the world and are part of the microbiota, 
which decomposes organic matter in soil and water. They 
also appear on the plants [41, 66]. Conant was the first to 
isolate Phialophora verrucosa from soil in 1937, thus proving 
saprophytic nature of these fungi. In Japan, P. verrucosa (n = 
17) and F. pedrosoi (n = 1) were isolated, mainly from rotting 
wood. Most of saprophytic strains were able to induce the 
infection in experimental animals [67].
Fonsecaea pedrosoi was isolated from the thorns of 
Mimosa pudica in the spot indicated by the patient with 
CBM where the infection probably occurred. However, 
F. pedrosoi was not isolated from the thorns of the plant 
in different locations, which suggests the “reservoir-type” 
of infection [66]. Rubin et al. described a well-document-
ed incident of an injury caused by a branch of the tree. 
F. pedrosoi was isolated from both the plant and the lesion 
[68].
Gezuele et al. reported a relatively high proportion 
(approx. 20%) of Phialophora verrucosa and Fonsecaea 
pedrosoi isolates in 328 samples of plant remains, soil 
and different materials, employing the method of mice 
inoculation and direct breeding. Out of 64 samples of 
dead parts of the trees and palm trunks, 32 contained 
one or both of the above fungal species. From 11% of soil 
samples that most frequently contained plant remains, 
pathogenic species were isolated. Scientists indicate the 
contrast between isolation of aetiological agents of CBM 
from the environment and a relatively rare occurrence of 
CBM in Uruguay [69].
Vicente et al. studied the appearance of the black 
yeast in the place of residence of patients with clin-
ical symptoms of CBM in Parana, Brazil. They found 
that strains isolated from the environment differ from 
common aetiological agents of CBM. The black yeast 
belonged to the same order, but constituted separate 
unknown species. They did not manage to isolate Fonse-
caea pedrosoi from 56 studied locations [70].
Characteristicsofpopulationaffected 
by chromoblastomycosis
In tropical and subtropical countries, the infection 
is more prevalent in males 30–50 years of age engaged 
in agriculture (approximately 70% of cases) [37, 46]. For 
instance, in Madagascar, 87% of patients with CBM are 
males above 16 years of age [62]. Minotto et al. observed 
the 4 : 1 male-to-female incidence ratio in Brazil. More-
over, the disease is most prevalent in farmers (aged 
50–60) [13]. It is explained by a more frequent engage-
ment of males in agricultural activities in those countries, 
which increases the possibility of injury with parts of 
plants affected by fungi responsible for CBM [66].
The inhibitory action of female sex hormones on 
fungal development is also postulated. A genetic sus-
ceptibility to the infection is also possible [71]. Interac-
tion between the host and the infecting fungus is still 
being analysed. Tsuneto et al. found that individuals with 
HLA-A29 antigen are more susceptible to infection. They 
demonstrated that in patients with CBM this antigen is 
10 times more frequent compared to the controls. No 
difference in susceptibility to CBM in relation to the race 
was observed [72].
In Japan, the male-to-female incidence ratio is nearly 
equal (1 : 0.8) [49]. Most frequently CBM occurs at 50 to 
80 years of age and affects mainly upper limbs, buttocks 
and lower limbs in males and upper limbs, neck, face and 
lower limbs in females [49].
No predilection of fungi for specific host tissues was 
found. The disease mostly affects lower limbs, especially 
feet which are most frequently exposed to contact with 
the infected material e.g. soil, plants or rotting wood [62, 
66]. Palms, arms and buttocks are also frequently infect-
ed. Lesions on ears, cornea, neck, face, breast, chest and 
stomach are occasionally described [13, 73–75].
Pathomorphology and pathophysiology  
of chromoblastomycosis
Pathomorphology
Tissue response to CBM is nonspecific and may be 
similar to the response in deep mycoses. Major changes 
observed in the area of the epidermis and keratinised 
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epidermis are hyperkeratosis and pseudoepitheliomatous 
hyperplasia. Few microulcerations with mycosis may be 
found [76]. Typical muriform cells (Medlar bodies) are 
usually observed in the epidermis, however they may 
change into filamentous forms, especially in the scabs 
covering lesions [77]. Muriform cells may divide and mul-
tiply by forming septa (septation). However, they never 
bud, which distinguishes them from the forms found in 
blastomycosis [2].
In the cutaneous and subcutaneous tissues, nonspe-
cific, diffuse infiltrations are observed (Figure 4).
Immunology of infection
It is still unknown which form of the fungus (hyphae, 
spores or sclerotic bodies) is the invasive form [78]. On 
the surface of the thorns of Mimosa pudica, the pres-
ence of hyphae and spores of F. pedrosoi was detected. 
However, sclerotic bodies, similar to those observed in 
the tissues of patients were found inside the thorns [66]. 
Preparing a special medium, which induces the produc-
tion of sclerotic bodies enabled to conduct studies with 
various forms of mycelium [79].
Neutrophils and macrophages are crucial cells in the 
immunological response in CBM. A typical reaction of 
granulation, regulated by polymorphonuclear neutro-
phils is observed in patients [76]. The first line of defence 
are dendritic cells. Dermal macrophages were shown to 
present fungal antigens in their cytoplasm. Similar prop-
erties were found in dermal dendrocytes and in Langer-
hans cells [80]. In patients with CBM those cells show 
an increased expression of CD 86, HLA-DR and CD 83 
receptors. In response to spores, dendritic cells produce 
TNF-α, IL-10 and IL-12. After F. pedrosoi antigen stimu-
lation, in patients with a severe form of CBM, dendritic 
cells produce large amounts of IL-10 and small amounts 
of IFN-γ [81].
CD4+ and CD8+ T lymphocyte populations, B lympho-
cytes and macrophages play a significant role in cell-me-
diated response [80]. Infecting thymus-deprived mice 
resulted in the development of the lesions characteristic 
of CBM, whereas in mice deprived of NK cells and mac-
rophages and in healthy mice, the lesions recovered 4– 
6 weeks after the infection [82]. A large number of scle-
rotic cells were found in the lesions. Delayed hypersen-
sitivity and antibodies against F. pedrosoi antigens were 
detected. Lymphocytes influence the immune response 
in CBM, which was confirmed by the fact that lympho-
cyte transfer from healthy mice resulted in full recovery 
within 2 months [82]. Further studies showed that immu-
nisation of mice with F. pedrosoi alive spores results in 
a massive inflow of CD4+ lymphocytes into lymph glands. 
Activated T lymphocytes demonstrate in vitro prolifera-
tion after another stimulation with a specific antigen and 
produce IFN-γ. Furthermore, the absence of CD4+ lym-
phocytes in mice results in more severe changes, delayed 
hypersensitivity and the production of lower amounts of 
IFN-γ in CBM compared with wild strains. The absence of 
CD8+ lymphocytes does not affect the above parameters 
[83]. A similar situation is observed in humans where in 
patients with severe forms of the disease, large amounts 
of IL-10 are produced, a low level of IFN-γ is found and 
isolated lymphocytes cannot proliferate. In mild cases 
of the disease, small amounts of IL-10 are found, a high 
level of IFN-γ and increased lymphocyte proliferation are 
also observed [84]. Studies indicate a crucial role of CD4+ 
T lymphocytes which produce IFN-γ as an immune de-
fence against F. pedrosoi [83, 84].
Hayakawa et al. found that the presence of aetiolog-
ical agents of CBM decreases the expression of MHC-II 
and CD8 receptors on macrophages, as well as nitric ox-
ide secretion by these receptors [85]. By using a specially 
prepared medium, da Silva et al. proved that these were 
spores, not sclerotic cells, that are responsible for the im-
pairment of the maturation of Langerhans cells, which 
was expressed by a decreased expression of CD40 and 
B7-2 receptors on their surface [86].
Langerhans cells are capable of phagocytising one, 
rarely two F. pedrosoi spores, while dermal macrophages 
are capable of internalising 4–5 spores. Langerhans cells 
do not phagocytise sclerotic bodies, although they may be 
adjoined to them [86]. The ability of phagocytising by mac-
rophages depends on a species of a fungus responsible for 
the infection of CBM and also on the presence of comple-
ment proteins. F. pedrosoi and Rhinocladiella aquaspersa 
are phagocytised more frequently compared to P. verru-
cosa and C. carrionii. Complement-dependent phagocy-
tosis occurs particularly in the case of P. verrucosa and 
R. aquaspersa [85]. Phagocytosis of the fungal cells is not 
related to their death. Little or lack of cytotoxic effect was 
demonstrated against F. pedrosoi, C. carrionii and P. verru-
cosa [85]. On the other hand, Langerhans cells prevent the 
growth of hyphae from both sclerotic cells and spores, re-
gardless of the presence of phagocytosis [79]. Bocca et al. 
reported that melanin present in F. pedrosoi cells inhibits 
the production of nitric oxide by macrophages [87].
In the studies on the causes of development of chron-
ic CBM, Sousa et al. found that C-type lectin receptor 
Mincle and Dectin-2 receptor are the major receptors 
related to the innate identification of F. pedrosoi [88]. It 
was demonstrated that the absence of inflammatory re-
action to F. pedrosoi infection is caused by the absence 
of innate immune response, and not by an immunosup-
pressive action of the fungus. The absence of response 
stimulation is caused by the absence of co-stimulation 
of the Toll-like receptor (TLR) pathway. Administration of 
the combination of F. pedrosoi spores and bacterial lipo-
polysaccharide triggers a strong inflammatory response. 
These antigens alone poorly stimulate TNF secretion, 
thereby it appears that administration of TLR agonists 
may serve as the therapy of CBM, also after their topical 
administration [88].
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Scientists emphasise that the host defence mecha-
nism against CBM has not been fully understood yet. The 
role of humoral response in controlling the disease still 
remains unknown. In serum of patients with CBM antimi-
crobial antibodies are detected. However, in healthy indi-
viduals who live in endemic regions and are in constant 
exposure to aetiological agents of CBM a specific humor-
al response is also present. The response, however, does 
not correlate in any way with the development of CBM. 
The time of seroconversion may be long, even as long as 
a year following the end of the therapy.
Clinical symptoms
The aetiological agent (i.e. fungal fragment) gains 
entrance through transcutaneous puncture wounds 
[68]. A primary lesion is represented by an erythematous 
papule or a warty growth, which gradually enlarges from 
the site of infection assuming various forms and sizes. 
The infection may occur anywhere on the body, however 
most frequently it affects limbs, especially feet and shins 
[37, 46]. Cases of buttock, trunk and face infection have 
also been reported [17, 37, 74, 89, 90]. In more advanced 
stages of the disease dissemination may occur in the 
form of satellite lesions which arise from scratching au-
toinoculation and spread via the lymphatic system [49]. 
Clinical changes progress slowly and frequently the peri-
od from infection to diagnosis is 10 years.
The disease can present clinically in 5 different forms: 
nodular, tumoral lesions, verrucous, plaque and cicatricial 
[1, 91]. 
Nodular type contains the youngest and the small-
est elements of the clinical picture of CBM. This type in-
cludes fairly soft, moderately raised, pale pink or purple 
nodules. The surface may be smooth, papillary or scaly. In 
further development of the lesions many nodules gradu-
ally transform into bigger tumoral lesions.
Tumoral type is represented by much bigger and 
more protruding, papillomatous, occasionally lobulated, 
tumour-like masses, partially or completely covered with 
dirty-grey epidermal remains, scabs and keratosis. On the 
feet and lower parts of the shin where the disease tends 
to be the most disseminated, tumoral masses frequently 
become huge in size and have a characteristic cauliflow-
er-like appearance.
Verrucous type is characterised by hyperkeratosis; 
lesions are verrucous in appearance and may resemble 
common warts (verruca vulgaris). Wart growth is fre-
quently noted along the edges of feet.
Plaque type is the least frequent form of CBM. It in-
cludes plano-convex lesions of various shapes and sizes, 
reddish to violet in colour and scaly on the surface.
Cicatricial type – these are the lesions on the skin 
level which develop by the peripheral growth with atro-
phic scarring, while in the centre of the lesion, the heal-
ing process occurs. Typically, the lesions are annular, 
arched or creeping within the lesion. They tend to cover 
substantial areas of the body.
Apart from the division presented above, the lesions 
in CBM may be classified according to their severity. 
Three levels are distinguished: 1) a mild form – single 
scales or nodules < 5 cm in diameter; 2) a moderate 
form – single or multiple lesions of tumoral, verrucous or 
plaque type isolated or conjoined, covering one or two 
adjacent body areas < 15 cm in diameter; and 3) a severe 
form includes any type of single or multiple lesions cover-
ing extensive skin areas, both neighbouring and distant. 
Severe lesions tend to poorly respond to treatment or 
become treatment-resistant.
Castro and de Andrade [3] by modifying the method 
of Restrepo et al. [92] assume an algorithm to determine 
the severity of the infection on the point scale: mild form 
(up to 3 points), moderate/intermediate form (4–6 points), 
severe form (7 and more points). Points are calculated ac-
cording to 4 criteria, i.e. the assessment of size, number of 
lesions, presence of complications and response to prior 
treatment. Pruritus (75%) and pain (55%) are reported with 
the co-existence of both in most cases [37].
Complications
Secondary infections and ulcerations are frequent 
CBM complications. Bonifaz et al. reported secondary 
bacterial infections in over 60% of patients [37]. In severe 
cases, lymphoedema [47, 93] and ankylosis occur. Foot 
and shin swelling leads to elephantiasis. Carcinogenesis, 
which is an infrequent serious complication of chronic 
CBM, results in the development of squamous cell car-
cinoma [94–97].
Invasive infections as a result of CBM are extremely 
rare. Nonetheless, F. pedrosoi was reported in brain ab-
scesses both in immune deficient patients and in immu-
nocompetent individuals [98–102]. It appears that a more 
frequent aetiological agent of disseminated infections is 
F. monophora, a species morphologically identical with 
F. pedrosoi [16].
Differentiation
Lesions in CBM are polymorphic and should be dif-
ferentiated from the lesions related to various medical 
conditions. To confirm the diagnosis, the presence of 
muriform cells (Medlar bodies) and the identification 
of an aetiological agent in the microbiological culture 
are necessary [1]. Many infectious diseases may pres-
ent similar symptoms to the ones found in CBM. These 
are fungal infections (including paracoccidioidomycosis, 
blastomycosis, coccidioidomycosis, phaeohyphomycosis, 
sporotrichosis, granulomatous candidiasis, trichophyto-
sis); bacterial infections (cutaneous tuberculosis, leprosy, 
tertiary syphilis, nocardiosis, ecthyma); mycobacterioses 
(caused by Mycobacterium marinum, M. fortuitum); par-
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asitic infections (leishmaniasis and rhinosporidiosis). 
Chromoblastomycosis should also be differentiated from 
non-infectious diseases such as planoepithelial carcino-
ma, psoriasis, sarcoidosis or lupus erythematous [1, 3].
Laboratory diagnosis 
Technically, diagnosis of CBM does not pose a great 
difficulty, however the average time between the oc-
currence of the disease and the diagnosis was 14 years, 
as reported by Minotto et al. [13]. Standard diagnosis is 
based on the presence of Medlar bodies in the potassium 
hydroxide-cleared specimen obtained from skin scrap-
ings or histopathologically.
Culture techniques
Microbiological culture is essential to determine an 
aetiological agent. For cultures, parts of the biopsy sam-
ple are used for growth in Sabouraud-agar (SGA) and Sa-
bouraud-agar supplemented with cycloheximide. Fungi, 
which are the aetiological agents of CBM grow slowly on 
the standard media and form black colonies. Macroscopic 
assessment of the colony and slide culture technique are 
employed in identification to assess microscope micro-
morphology and types of sporulation. Molecular biology 
techniques are useful and essential to differentiate some 
species. According to some definitions of CBM, an iso-
lated fungus must belong to the Chaetothyriales order 
[1] (cf. a chapter on aetiological agents). Therefore, the 
correct identification of the species is essential for the 
correct diagnosis.
Direct examination
The specimen is obtained from skin scrapings from 
the lesion. Sclerotic bodies are easily observed in potas-
sium hydroxide-cleared specimens with dimethyl sulfox-
ide. Typical golden-brown sclerotic cells (Medlar bodies) 
and other elements of the mycelium are the objective of 
examination.
Histopathology
Biopsy is performed to confirm the diagnosis. In most 
cases, tuberculoid-type granulomas are reported, consist-
ing of lymphohistiocytic infiltration, epithelial cells and 
Langhans multinucleated giant cells (Langhans giant cell 
is a large cell formed by the fusion of epithelioid cells 
(macrophages activated as a result of a continuous activi-
ty of cytokines in delayed hypersensitivity), characteristic 
of many granulomatous conditions.) Sclerotic bodies are 
found in the stratum corneum and the following layers 
of the epidermis and the skin. Sclerotic bodies may also 
be found in the granulomatous processes and in the gi-
ant cells. Special staining is not necessary to observe the 
lesions as they are easily observed in haematoxylin-eosin 
stained tissues [37].
Different techniques
Imaging techniques and serology are not typically 
employed in the diagnosis. In molecular diagnosis, du-
plex PCR of ribosomal DNA for Fonsecaea spp. [103] and 
a special oligonucleotide primer for C. carrionii identifica-
tion are used [104].
Treatment
The disease is related to a low cure ratio and high re-
lapse ratio, especially in chronic and extensive infections. 
The choice of the treatment and the success of the ther-
apy depend on the aetiological agent, size, extent and 
location of the lesion. The presence of complications is 
a significant factor affecting the treatment. Skin fibrosis 
and oedema decrease drug bioavailability in the tissue 
[105, 106]. In patients with early and small lesions, the 
aim of treatment is a complete cure. However, in the case 
of extensive lesions even long-term treatment may not 
be successful and may only result in reduction and con-
trol of the disease to prevent complications.
Bonifaz et al. analysed 51 cases of CBM and report-
ed a cure in 31% of patients, improvement in 57% and 
treatment failure in 12% of patients. The most common 
method was cryosurgery for small lesions, itraconazole 
treatment for extensive lesions and the combination of 
both methods [37].
Clinical cure is defined as a complete resolution of 
the lesions, typically with the remaining sclerotic scar. 
Mycological cure is defined as the absence of the fungus 
in microscopic specimens and the absence of growth in 
cultures [105].
Three treatment methods of CBM can be distin-
guished: antifungal chemotherapy, physicochemical 
methods and the combination of both.
Antifungal chemotherapy
Itraconazole. In the treatment of CBM, daily doses 
of 200 mg or 400 mg of itraconazole are administered, 
depending on the severity of the infection [107]. Mild 
and moderate forms (Castro and de Andrade [3]) may be 
successfully cured after 6–12 months [92, 106, 108]. Se-
vere forms tend to show a significant improvement after 
several months of the therapy, however long-term cure 
is rarely observed. After the termination of the therapy, 
relapses are frequently noted [26], presumably because 
itraconazole is not an antifungal but fungistatic agent.
Itraconazole has been successfully employed in the 
pulse therapy (400 mg/day for a week, every month). 
This therapy reduces the amount of the drug and, conse-
quently, the cost of the therapy. However, it is question-
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able whether this mode of dosage produces resistance 
to the drug [109, 110]. 
In the literature, there are isolated reports on the use 
of itraconazole in conjunction with cryosurgical methods, 
5-fluorocytosine or amphotericin B.
Terbinafine. Terbinafine demonstrates an antifungal 
activity in vitro against aetiological agents of CBM. Es-
terre et al. proved that the drug has an antifibrotic action 
in the treatment of CBM [40]. The recommended daily 
dose is 500–1000 mg [107, 111]. Efficacy of lower doses 
(250 mg/day) is also reported [112]. Due to the mecha-
nism of action of terbinafine, the risk of side effects in 
long-term therapy is minimal.
Posaconazole. The recommended dose is 800 mg/
day. Treatment is characterised by good efficacy and tol-
erance. However, it is related to very high costs of the 
therapy [107, 113].
5-fluorocytosine (5-FC). By the 1980s, 5-fluorocyto-
sine had been a drug of choice in CBM. However, incon-
sistent results were noted in both mono- and combined 
therapy [114]. The recommended dose was 100–150 mg/
kg/day in four doses for 6–12 months. Moreover, a 10% 
solution of the drug could be administered topically in 
the form of an occlusive dressing. F. pedrosoi may devel-
op resistance to 5-fluorocytosine in vitro.
Physical methods
Surgical excision of the lesion in CBM, although 
performed, is not recommended. It is believed that sur-
gical manipulation in the area of the lesion may favour 
the dissemination of the disease. Therefore, it should be 
performed only in selected cases [3].
Primary limited lesions are usually treated surgical-
ly. Cryotherapy is performed, frequently conjoined with 
itraconazole therapy. Malagasy doctors use cautery in 
conjunction with terbinafine therapy.
Cryosurgery. Cryosurgical methods involving liquid 
nitrogen in the treatment of CBM were first employed 
in 1973 in Mexico, by Manuel Medina-Ramirez [115]. In 
1989, a study was published on treatment assessment of 
a greater number of CBM patients. The time of cryotherapy 
ranges from 30 s to 4 min, depending on the authors. Also 
cycles vary, from a single procedure to over forty proce-
dures. In the case of localised lesions, in 5 patients, treat-
ment response was very good without the presence of re-
lapses within four and a half years after the procedure [34].
Chromoblastomycosis was successfully treated with 
cryotherapy combined with itraconazole therapy [111, 
116]. It is unknown how the cure is achieved. The fungi 
are eliminated from lesions as late as 1–2 weeks after the 
therapy, which excludes the possibility of a direct influ-
ence of the cold on fungal cells and indicates the immune 
mechanism [117, 118].
Thermotherapy. The literature, mainly of Japanese 
authors from the late 1970s and the early 1980s, provides 
reports on the local treatment with “pocket warmers” 
placed on the lesion 24 h/day for a couple of months 
[119–122].
The mechanism of action relies on fungal intolerance 
to high temperature. Limited availability of pocket warm-
ers in tropical countries where CBM is prevalent limits 
the therapy to developed countries with a temperate 
climate [3]. 
Thermotherapy was employed in conjunction with 
antifungal chemotherapy: itraconazole, terbinafine and 
5-fluorocytosine [123, 124].
Laser vaporisation. Laser vaporisation is a highly 
promising method which is an alternative method of 
CBM treatment. A combination of laser vaporisation and 
thermotherapy has been reported to successfully eradi-
cate CBM lesions in patients with relapses of the disease 
[125, 126]. This approach was employed as the only meth-
od for the removal of buttock lesions in Germany [127].
Drug sensitivity test
As yet there have been no standardised methods to 
assess sensitivity of dimorphic and filamentous fungi to 
drugs in vitro. In vitro drug-resistance assessment can 
only prove microbiological resistance of the microorgan-
ism, but it cannot be employed to predict a clinical re-
sponse [106].
There were reports on drug resistance to itraconazole 
by F. pedrosoi spp. isolated from patients on long-term 
itraconazole treatment [128]. 
Summary 
Although CBM has been known for 100 years, it still 
remains an unresolved clinical problem. Relapses are 
frequently reported. Also, many issues regarding aeti-
ological agents, their appearance in the environment, 
geographical distribution and pathogenicity need to be 
addressed. Host genetic susceptibility to the disease and 
the immune system response mechanism should be con-
sidered.
References
1. Queiroz-Telles F, Esterre P, Perez-Blanco M, et al. Chromo-
blastomycosis: an overview of clinical manifestations, diag-
nosis and treatment. Med Mycol 2009; 47: 3-15.
2. Ajello L. The gamut of human infections caused by demati-
aceous fungi. Jpn J Med Mycol 1981; 22: 1-5.
3. Castro LGM, de Andrade TS. Chromoblastomycosis: still 
a therapeutic challenge. Expert Review of Dermatology 
2010; 5: 433-44.
4. Schwartz R, Baran E. Chromoblastomycosis e-medicine from 
WebMD, 2010. Available at: http://emedicine.medscape.
com/article/1092695-overview.
5. Odds FC, Arai T, Disalvo AF, et al. Nomenclature of fungal 
diseases: a report and recommendations from a sub-com-
Postępy Dermatologii i Alergologii 5, October / 2014 
Chromoblastomycosis
319
mittee of the international society for human and animal 
mycology (isham). J Med Vet Mycol 1992; 30: 1-10.
6. Pedroso A, Gomes JM. 4 casos de dermatite verrucosa pro-
duzida pela phialophora verrucosa. Anais Paulistas de Me-
dicina e Cirurgia 1920; 11: 53-61.
7. Castro RM, Castro LG. On the priority of description of chro-
momycosis. Mykosen 1987; 30: 397-403.
8. Rudolph M. Uber die brasilianische (figueira). Archiv für 
Schiffs- und Tropen-Hygiene 1914; 18: 498.
9. Medlar EM. A cutaneous infection caused by a new fungus 
phialophora verrucosa with a study of the fungus. J Med 
Res 1915; 32: 507-22.
10. Lane CG. A cutaneous disease caused by a new fungus phi-
alophora verrucosa. J Cutan Dis 1915; 33: 840-6.
11.  Brumpt E. Precis de parasitologie. Masson & Cie, Paris 1922.
12. Terra F, Torres M, Fonseca FO, et al. Novo tipo de dermatite 
verrucosa: micose por acrotheca com associação de leish-
maniose. Brasil Medico 1922; 36: 363-8.
13. Minotto R, Bernardi CDV, Mallmann LF, et al. Chromoblasto-
mycosis: a review of 100 cases in the state of rio grande do 
sul, Brazil. J Am Acad Dermatol 2001; 44: 585-92.
14. Trejos A. Cladosporium carrionii n. sp. and the problem of 
cladosporia isolated from chromoblastomycosis. Rev Biol 
Trop 1954; 2: 75-112.
15. Abliz P, Fukushima K, Takizawa K, et al. Identification of 
pathogenic dematiaceous fungi and related taxa based on 
large subunit ribosomal dna d1/d2 domain sequence anal-
ysis. FEMS Immunology and Medical Microbiology 2004; 40: 
41-9.
16. de Hoog GS, Vicente A, Gerrits van den Ende AHG, et al. 
Molecular ecology and pathogenic potential of fonsecaea 
species. Medical Mycology 2004; 42: 405-16.
17. Arango M, Jaramillo C, Cortés A, et al. Auricular chromo-
blastomycosis caused by rhinocladiella aquaspersa. Medical 
Mycology 1998; 36: 43-5.
18. Badali H, Bonifaz A, Barrón-Tapia T, et al. Rhinocladiella 
aquaspersa, proven agent of verrucous skin infection and 
a novel type of chromoblastomycosis. Med Mycol 2010; 48: 
696-703.
19. Hoffmann CD, Danucalov IP, Purim KS, et al. Infections 
caused by dematiaceous fungi and their anatomoclinical 
correlations. An Bras Dermatol 2011; 86: 138-41.
20. Kinkead S, Jancic V, Stasko T, et al. Chromoblastomycosis in 
a patient with a cardiac transplant. Cutis 1996; 58: 367-70.
21. Naka W, Harada T, Nishikawa T, et al. A case of chromoblas-
tomycosis: with special reference to the mycology of the 
isolated exophiala jeanselmei. Mycoses 1986; 29: 445-52.
22. Barba-Gómez JF, Mayorga J, McGinnis MR, et al. Chromo-
blastomycosis caused by exophiala spinifera. J Am Acad 
Dermatol 1992; 26: 367-70.
23. Develoux M, Dieng MT, Ndiaye B, et al. Chromomycosis 
caused by exophilia spinifera in sahelian Africa. Annales de 
Dermatologie et de Venereologie 2006; 133: 68-9.
24. Padhye AA, Hampton AA, Hampton MT, et al. Chromoblasto-
mycosis caused by exophiala spinifera. Clin Infect Dis 1996; 
22: 331-5.
25. Tomson N, Abdullah A, Maheshwari MB. Chromomycosis 
caused by exophiala spinifera. Clin Exp Dermatol 2006; 31: 
239-41.
26. Najafzadeh MJ, Rezusta A, Cameo MI, et al. Successful treat-
ment of chromoblastomycosis of 36 years duration caused 
by fonsecaea monophora. Med Mycol 2010; 48: 390-3.
27. Xi L, Lu C, Sun J, et al. Chromoblastomycosis caused by 
a meristematic mutant of fonsecaea monophora. Med My-
col 2009; 47: 77-80.
28. Najafzadeh MJ, Sun J, Vicente V, et al. Fonsecaea nubica sp. 
nov, a new agent of human chromoblastomycosis revealed 
using molecular data. Med Mycol 2010; 48: 800-6.
29. Son YM, Kang HK, Na SY, et al. Chromoblastomycosis caused 
by phialophora richardsiae. Ann Dermatol 2010; 22: 362-6.
30. Gueidan C. Chaetothyriales. version 29 January 2008 
(under construction). http://tolweb.org/chaetothyria-
les/29305/2008.01.29 in the tree of life web project http://
tolweb.org/Chaetothyriales/29305/2008.01.29 in The Tree 
of Life Web Project, 2008.
31. Najafzadeh MJ, Gueidan C, Badali H, et al. Genetic diversity 
and species delimitation in the opportunistic genus fonse-
caea. Med Mycol 2009; 47: 17-25.
32. Redondo-Bellón P, Idoate M, Rubio M, et al. Chromoblas-
tomycosis produced by aureobasidium pullulans in an im-
munosuppressed patient. Arch Dermatol 1997; 133: 663-4.
33. Chowdhary A, Guarro J, Randhawa HS, et al. A rare case of 
chromoblastomycosis in a renal transplant recipient caused 
by a non-sporulating species of rhytidhysteron. Med Mycol 
2008; 46: 163-6.
34. Pimentel ER, Castro LG, Cuce LC, et al. Treatment of chro-
momycosis by cryosurgery with liquid nitrogen: a report on 
eleven cases. J Dermatol Surg Oncol 1989; 15: 72-7.
35. Campolina SS, Caligiorne RB, Rezende-Silva S, et al. A skin 
infection mimicking chromoblastomycosis by a capnodi-
alean fungus. Med Mycol 2009; 47: 81-5.
36. Crous PW, Braun U, Groenewald JZ. Mycosphaerella is poly-
phyletic. Stud Mycol 2007; 58: 1-32.
37. Bonifaz A, Carrasco-Gerard E, Saul A. Chromoblastomyco-
sis: clinical and mycologic experience of 51 cases. Mycoses 
2001; 44: 1-7.
38. Diáz Almeida JG, Taboas González M, Dube A. Chromoblas-
tomycosis in cuba, retrospective clinical and epidemiologic 
studies of 72 patients. Rev Cubana Med Trop 1978; 30: 95-108.
39. Perez-Blanco M, Hernández Valles R, García-Humbría L, et 
al. Chromoblastomycosis in children and adolescents in the 
endemic area of the falcón state, Venezuela. Med Mycol 
2006; 44: 467-71.
40. Restrepo-Moreno A, Calle Velez G, Sanchez-Arbelaez J, et 
al. A review of medical mycology in Colombia, south Ameri-
ca – including presentation of 309 original cases of various 
mycoses. Mycopathologia et Mycologia Applicata 1962; 17: 
93-110.
41. Marques SG, Silva CDM, Saldanha PC, et al. Isolation of 
fonsecae pedrosoi from the shell of the babassu coconut 
orbignya phalerata martius in the Amazon region of mara-
nhao Brazil. Nihon Ishinkin Gakkai Zasshi 2006; 47: 305-11.
42. Silva JP, de Souza W, Rozental S. Chromoblastomycosis: 
a retrospective study of 325 cases on amazonic region (Bra-
zil). Mycopathologia 1998; 143: 171-5.
43. Montpellier J, Catamei A. Mycose humaine due a un cham-
pignion du genre "Hormodendron: H. algeriensis, nov. sp.". 
Ann Derm Syph 1927; 8: 626-35.
44. Esterre P, Andriantsimahavandy A, Ramarcel ER, et al. Forty 
years of chromoblastomycosis in Madagascar: a review. Am 
J Trop Med Hyg 1996; 55: 45-7.
45. Fukushiro R. Chromomycosis in Japan. Int J Dermatol 1984; 
22: 221-9.
46. Attapattu MC. Chromoblastomycosis – a clinical and my-
cological study of 71 cases from Sri Lanka. Mycopathologia 
1997; 137: 145-51.
Postępy Dermatologii i Alergologii 5, October / 2014320
Paweł M. Krzyściak, Małgorzata Pindycka-Piaszczyńska, Michał Piaszczyński
47. Sharma N, Marfatia YS. Genital elephantiasis as a compli-
cation of chromoblastomycosis: a diagnosis overlooked. 
Indian Journal of Sexually Transmitted Diseases and AIDS 
2009; 30: 43-45.
48. Xi L, Sun J, Lu C, et al. Molecular diversity of fonsecaea (cha-
etothyriales) causing chromoblastomycosis in southern Chi-
na. Med Mycol 2009; 47: 27-33.
49. Kondo M, Hiruma M, Nishioka Y, et al. A case of chromo-
mycosis caused by fonsecaea pedrosoi and a review of 
reported cases of dematiaceous fungal infection in Japan. 
Mycoses 2005; 48: 221-5.
50. Leslie DF, Beardmore GL. Chromoblastomycosis in 
queensland: a retrospective study of 13 cases at the royal 
Brisbane hospital. Australas J Dermatol 1979; 20: 23-30.
51. Santos LD, Arianayagam S, Dwyer B, et al. Chromoblastomy-
cosis: a retrospective study of six cases at the royal Darwin 
hospital from 1989 to 1994. Pathology 1996; 28: 182-7.
52. Tschernjawski J. Chromoblastomycosis. Archiv für Dermatol-
ogie und Syphilis 1928; 157: 196-206.
53. Symmers WSC. Chromoblastomycosis simulating rhino-
sporidiosis in a patient from Ceylon. J Clin Path 1960; 13: 
287-90.
54. Sonck CE. Chromoblastomycosis: five cases from Finland. 
Acta Dermato-Venereologica 1959; 39: 300-9.
55. Chmel L, Svobodova Y, Ranincova A. 1st case of chromoblas-
tomycosis in the Czechoslovakia srr. Cesk Dermatol 1963; 
38: 145-50.
56. Horácek J, Ulicná L. The 3d case of chromomycosis in Czecho-
slovakia. Cesk Dermatol 1969; 44: 118-20.
57. Otcenásek M, Hubálek Z, Dvorák J, et al. Another clinical 
case of chromomycosis in Czechoslovakia? Mykosen 1968; 
11: 719-24.
58. Koch HA, Goeltner E. Phialophora pedrosoi als erreger der 
chromomykose in Deutschland. Dermatologische Wochen-
schrift 1964; 150: 577-81.
59. Kowalska M, Hański W, Bieluńska S. Pierwszy przypadek 
chromomikozy w Polsce. Przegl Dermatol 1972; 59: 349-53.
60. Pindycka-Piaszczyńska M, Krzyściak P, Piaszczyński M, et al. 
Chromoblastomycosis as an endemic disease in temperate 
europe: first confirmed case and review of the literature. 
Eur J Clin Microbiol Infect Dis 2014; 33: 391-8.
61. Azad K, Khanna G, Capoor MR, et al. Cladophialophora car-
rionii: an aetiological agent of cutaneous chromoblastomy-
cosis from a non-endemic area, north India. Mycoses 2011; 
54: 217-9.
62. Esterre P, Andriantsimahavandy A, Raharisolo C. Natural 
history of chromoblastomycosis in Madagascar and the In-
dian Ocean. Bull Soc Pathol Exot 1997; 90: 312-7.
63. Yaguchi T, Tanaka R, Nishimura K, et al. Molecular phyloge-
netics of strains morphologically identified as fonsecaea pe-
drosoi from clinical specimens. Mycoses 2007; 50: 255-60.
64. Lim SW, Suh MK, Kang GS, et al. Molecular phylogenetics 
of fonsecaea strains isolated from chromoblastomycosis 
patients in South Korea. Mycoses 2011; 54: e415-20.
65. Najafzadeh MJ, Sun J, Vicente VA, et al. Molecular epidemi-
ology of fonsecaea species. Emerg Infect Dis 2011; 17: 464-9.
66. Salgado CG, da Silva JP, Diniz JA, et al. Isolation of fonsecaea 
pedrosoi from thorns of mimosa pudica, a probable natu-
ral source of chromoblastomycosis. Revista Do Instituto De 
Medicina Tropical De Sao Paulo 2004; 46: 33-6.
67. Iwatsu T, Okamoto S. Isolation of phialophora verrucosa and 
fonsecaea pedrosoi from nature in Japan. Mycopathologia 
1981; 75: 149-58.
68. Rubin HA, Bruce S, Rosen T, et al. Evidence for percutaneous 
inoculation as the mode of transmission for chromoblasto-
mycosis. J Am Acad Dermatol 1991; 25: 951-4.
69. Gezuele E, Mackinnon JE, Conti-Díaz IA. The frequent iso-
lation of phialophora verrucosa and phialophora pedrosoi 
from natural sources. Sabouraudia 1972; 10: 266-73.
70. Vicente VA, Attili-Angelis D, Piem MR, et al. Environmental 
isolation of black yeast-like fungi involved in human infec-
tion. Stud Mycol 2008; 61: 137-44.
71. Hernandez-Hernandez F, De Bievre C, Camacho-Arroyo I, et 
al. Sex hormone effects on phialophora verrucosa in vitro 
and characterization of progesterone receptors. J Med Vet 
Mycol 1995; 33: 235-9.
72. Tsuento LT, Arce-Gomez B, Petzl-Erler ML, et al. Hla-a29 and 
genetic susceptibility to chromoblastomycosis. J Med Vet 
Mycol 1989; 27: 181-5.
73. Bittencourt AL, Londero AT, Andrade JAF. Cromoblastomiose 
auricular. Relato de um caso. Revista do Instituto de Medici-
na Tropical de Sao Paulo 1994; 36: 181-3.
74. França K, Villa RT, de Azevedo Bastos VR, et al. Auricular 
chromoblastomycosis: a case report and review of pub-
lished literature. Mycopathologia 2011; 172: 69-72.
75. Hofling-Lima AL, Guarro J, Freitas D, et al. Clinical treatment 
of corneal infection due to fonsecaea pedrosoi – case re-
port. Arq Bras Oftalmol 2005; 68: 270-2.
76. Uribe F, Zuluaga AI, Leon W, et al. Histopathology of chro-
moblastomycosis. Mycopathologia 1989; 105: 1-6.
77. Lee MW, Hsu S, Rosen T. Spores and mycelia in cutaneous 
chromomycosis. J Am Acad Dermatol 1998; 39: 850-2.
78. Salgado CG. Fungal x host interactions in chrmoblastomy-
cosis. Virulence 2010; 1: 3-5.
79. da Silva MB, da Silva JP, Sirleide Pereira YS, et al. Develop-
ment of natural culture media for rapid induction of fonse-
caea pedrosoi sclerotic cells in vitro. J Clin Microbiol 2008; 
46: 3839-41.
80. Sotto MN, Brito TD, Silva AMG, et al. Antigen distribution 
and antigen-presenting cells in skin biopsies of human 
chromoblastomycosis. J Cutan Pathol 2004; 31: 14-8.
81. Mazo Fávero Gimenes V, Da Glória de Souza M, Ferreira KS, 
et al. Cytokines and lymphocyte proliferation in patients 
with different clinical forms of chromoblastomycosis. Mi-
crobes Infect 2005; 7: 708-13.
82. Ahrens J, Graybill JR, Abishawl A, et al. Experimental murine 
chromomycosis mimicking chronic progressive human dis-
ease. Am J Trop Med Hyg 1989; 40: 651-8.
83. Teixeira de Sousa MG, Ghosn EEB, Almeida SR. Absence 
of CD4+ T cells impairs host defence of mice infected with 
fonsecaea pedrosoi. Scand J Immunol 2006; 64: 595-600.
84. Gimenes VMF, De Souza MG, Ferreira KS, et al. Cytokines 
and lymphocyte proliferation in patients with different clini-
cal forms of chromoblastomycosis. Microbes Infect 2005; 7: 
708-13.
85. Hayakawa M, Ghosn EEB, de Sousa MGT, et al. Phagocy-
tosis, production of nitric oxide and pro-inflammatory cy-
tokines by macrophages in the presence of dematiaceus 
fungi that causes chromoblastomycosis. Scand J Immunol 
2006; 64: 382-7.
86. da Silva JP, da Silva MB, Slagado UI, et al. Phagocytosis of 
fonsecaea pedrosoi conidia, but not sclerotic cells caused by 
langerhans cells, inhibits cd40 and b7-2 expression. FEMS 
Immunol Med Microbiol 2007; 50: 104-11.
87. Bocca AL, Brito PPMS, Figueiredo F, et al. Inhibition of nitric 
oxide production by macrophages in chromoblastomyco-
sis: a role for fonsecaea pedrosoi melanin. Mycopathologia 
2006; 161: 195-203.
Postępy Dermatologii i Alergologii 5, October / 2014 
Chromoblastomycosis
321
88. Sousa MDG, Reid DM, Schweighoffer E, et al. Restoration 
of pattern recognition receptor costimulation to treat chro-
moblastomycosis, a chronic fungal infection of the skin. 
Cell Host Microbe 2011; 9: 436-43.
89. De A, Gharami RC, Datta PK. Verrucous plaque on the face: 
what is your diagnosis? Dermatol Online J 2010; 16: 6.
90. Gross DJ, Schosser RH. Chromomycosis on the nose. Arch 
Dermatol 1991; 127: 1831-2, 1834-5.
91. Carrion A. Chromoblastomycosis. Annls New York Academy 
Science 1950; 50: 1255-82.
92. Restrepo A, Gonzalez A, Gomez I, et al. Treatment of chro-
moblastomycosis with itraconazole. Annals of the New 
York Academy of Science 1988; 544: 504-16.
93. Ogawa MM, Alchorne MM, Barbieri A, et al. Lymphoscin-
tigraphic analysis in chromoblastomycosis. Int J Dermatol 
2003; 42: 622-5.
94. Esterre P, Pecarrère JL, Raharisolo C, et al. Carcinome épi-
dermoïde développé sur des lésions de chromomycose. 
[Squamous cell carcinoma arising from chromomycosis. 
report of two cases]. Ann Pathol 1999; 19: 516-20.
95. Foster HM, Harris TJ. Malignant change (squamous carci-
noma) in chronic chromoblastomycosis. Aust N Z J Surg 
1987; 57: 775-7.
96. Jamil A, Lee YY, Thevarajah S. Invasive squamous cell carci-
noma arising from chromoblastomycosis. Med Mycol 2012; 
50: 99-102.
97. Torres E, Beristain JG, Lievanos Z, et al. Chromoblastomyco-
sis associated with a lethal squamous cell carcinoma. An 
Bras Dermatol 2010; 85: 267-70.
98. Al-Hedaithy SS, Jamjoom ZA, Saeed ES. Cerebral phaeohy-
phomycosis caused by fonsecaea pedrosoi in Saudi Arabia. 
APMIS: Acta Pathologica, Microbiologica, et Immunologica 
Scandinavica 1988; 3: 94-100.
99. McGinnis M. Chromoblastomycosis and phaeohyphomy-
cosis: new concepts, diagnosis and mycology. J Am Acad 
Dermatol 1983; 8: 1-16.
100. Nobrega JP, Rosemberg S, Adami AM, et al. Fonsecaea pe-
drosoi cerebral phaeohyphomycosis (‘‘chromoblastomyco-
sis’’): first human culture-proven case reported in Brazil. 
Revista do Instituto de Medicina Tropical de Sao Paulo 
2003; 45: 217-20.
101.  Saberi H, Kashfi A, Hamidi S, et al. Cerebral phaeohypho-
mycosis masquerading as a parafalcian mass: case report. 
Surg Neurol 2003; 60: 354-9.
102.  Santosh V, Khanna N, Shankar SK, et al. Primary mycotic 
abscess of the brain caused by fonsecaea pedrosoi. Case 
report. J Neurosurg 1995; 82: 128-30.
103.  de Andrade TS, Cury AE, de Castro LG, et al. Rapid identifi-
cation of fonsecaea by duplex polymerase chain reaction 
in isolates from patients with chromoblastomycosis. Diagn 
Microbiol Infect Dis 2007; 57: 267-72.
104.  Abliz P, Fukushima K, Takizawa K, et al. Specific oligonu-
cleotide primers for identification of cladophialophora 
carrionii, a causative agent of chromoblastomycosis. J Clin 
Microbiol 2004; 42: 404-7.
105.  Ameen M. Chromoblastomycosis: clinical presentation and 
management. Clin Exp Dermatol 2009; 34: 849-54.
106.  Esterre P, Queiroz-Telles F. Management of chromoblasto-
mycosis: novel perspectives. Curr Opin Infect Dis 2006; 19: 
148-52.
107. Ameen M. Managing chromoblastomycosis. Tropical Doctor 
2010; 40: 65-7.
108. Queiroz-Telles F, Purim KS, Fillus JN, et al. Itraconazole in 
the treatment of chromoblastomycosis due to fonsecaea 
pedrosoi. Int J Dermatol 1992; 31: 805-12.
109.  Kumarasinghe SPW, Kumarasinghe MP. Itraconazole pulse 
therapy in chromoblastomycosis. Eur J Dermatol 2000; 10: 
220-2.
110.  Ungpakorn R, Reangchainam S. Pulse itraconazole 400 mg 
daily in the treatment of chromoblastomycosis. Clin Exp 
Dermatol 2006; 31: 245-7.
111.  Bonifaz A, Martinez-Soto E, Carrasco-Gerard E, et al. Treat-
ment of chromoblastomycosis with itraconazole, cryosur-
gery and a combination of both. Int J Dermatol 1997; 36: 
542-7.
112.  Sevigny GM, Ramos-Caro FA. Treatment of chromoblasto-
mycosis due to fonsecaea pedrosoi with low-dose terbina-
fine. Cutis 2000; 66: 45-6.
113.  Negroni R, Tobón A, Bustamante B, et al. Posaconazole 
treatment of refractory eumycetoma and chromoblasto-
mycosis. Revista do Instituto de Medicina Tropical de Sao 
Paulo 2005; 47: 339-46.
114.  Bonifaz A, Paredes-Solis V, Saul A. Treating chromoblasto-
mycosis with systemic antifungals. Expert Opin Pharmaco-
ther 2004; 5: 247-54.
115.  Medina-Ramirez M. Treatment of chromomycosis with liq-
uid nitrogen. Int J Dermatol 1973; 12: 250-4.
116.  Kullavanijaya P, Rojanavanich V. Successful treatment of 
chromoblastomycosis due to fonsecaea pedrosoi by the 
combination of itraconazole and cryotherapy. Int J Derma-
tol 1995; 34: 804-7.
117.  Castro LGM. Mecanismo de cura da cromomicose pela crio-
cirurgia com nitrogenio liquido. An Bras Dermatol 1989; 64: 
297-300.
118.  Castro LGM, Pimentel ERA, Lacaz CS. Treatment of chro-
momycosis by cryosurgery with liquid nitrogen: 15 years’ 
experience. Int J Dermatol 2003; 42: 408-12.
119.  Kikuchi Y, Kondo M, Yaguchi H, et al. A case of chromomy-
cosis caused by fonsecaea pedrosoi presenting as a small 
plaque on the left upper arm: a review of reported cases of 
dematiaceous fungal infection in japan. Japan J Med Mycol 
2007; 48: 85-9.
120.  Tagami H, Ohi M, Aoshima T. Topical heat therapy for cuta-
neous chromomycosis. Arch Dermatol 1979; 115: 740-1.
121.  Tagami H, Ginoza M, Imaizumi S, et al. Successful treat-
ment of chromoblastomycosis with topical heat therapy. 
J Am Acad Dermatol 1984; 10: 615-9.
122.  Yanase K, Yamada M. “Pocket-warmer” therapy of chromo-
mycosis. Arch Dermatol 1978; 114: 1095.
123.  Tanuma H, Hiramatsu M, Mukai H, et al. A case of chro-
moblastomycosis effectively treated with terbinafine. char-
acteristics of chromoblastomycosis in the Kitasato region, 
Japan. Mycoses 2000; 43: 79-83.
124.  Usuki K, Yotsumoto S, Hamada H, et al. A case of chro-
momycosis with tumor-like growth. J Dermatol 1996; 23: 
643-7.
125.  Hira K, Yamada H, Takahashi Y, et al. Successful treatment 
of chromomycosis using carbon dioxide laser associated 
with topical heat applications. J Eur Acad Dermatol Vene-
reol 2002; 16: 273-5.
126.  Kuttner BJ, Siege RJ. Treatment of chromomycosis with CO2 
laser. J Dermatol Surg Oncol 1986; 12: 965-8.
127.  Tsianakas A, Pappai D, Basoglu Y, et al. Chromomycosis 
– successful CO2 laser vaporization. J Eur Acad Dermatol 
Venereol 2008; 22: 1385-6.
128.  Andrade TS, Castro LG, Nunes RS, et al. Susceptibility of 
sequential fonsecaea pedrosoi isolates from chromoblas-
tomycosis patients to antifungal agents. Mycoses 2004; 
47: 216-21.
